Alnylam Assist™: Patient Support Program

Alnylam Assist™ will provide support for your patients as they begin treatment with OXLUMO

Our Case Managers are here to help your patients.

Call Us:


Monday - Friday, 8am - 6pm

Enroll Your Patients

How Alnylam Assist™ Can Help

Alnylam Assist is committed to providing your patient support throughout treatment with OXLUMO. Alnylam Assist offers support services to your patient in 4 key areas:

Alnylam Assist® - Understanding Your Benefits

Benefit Verification

Help determining
patient-specific coverage

Alnylam Assist® - Financial Assistance Options

Financial Assistance

Information about patients'
eligibility for financial assistance

Alnylam Assist® - Disease and Treatment Education

Patient Education

Disease and product education
for patients and families

Alnylam Assist® Reimbursement Support Icon

Treatment Access

Education about the prior authorization,
claims, and appeals processes

Forms and Documents

Download the materials below for more information about Alnylam Assist

See All Forms and Documents ›

Alnylam Assist® - Downloadable PDF

Healthcare Professionals

Alnylam Assist™ Support
Services Overview Brochure


Alnylam Assist® - Downloadable PDF

Patients + Caregivers

Alnylam Assist™ Brochure


Alnylam Assist® Case Managers

Enroll Your Patients

After deciding to prescribe your patient OXLUMO, consider enrolling your patient in Alnylam Assist™.

Alnylam Assist® Case Managers


Monday - Friday, 8am - 6pm

Enroll Your Patients

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›


Alnylam Assist® Start Form - To Print And Fax

& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle


Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.


OXLUMO® (lumasiran) is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.